Misplaced Pages

5-Methyl-MDA

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	CA: Schedule I DE: NpSG (Industrial and scientific use only) UK: Class A US: Analogue to a Schedule I/II drug (possibly, if human consumption intent can be proven)
Identifiers
IUPAC name 1-(7-methyl-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number	749191-14-8 204916-89-2 (HCl)
PubChem CID	10012829
ChemSpider	8188403
UNII	10R3PP3FVM
ChEMBL	ChEMBL6330
CompTox Dashboard (EPA)	DTXSID101024547
Chemical and physical data
Formula	C11H15NO2
Molar mass	193.246 g·mol
3D model (JSmol)	Interactive image
SMILES O2COc1c2cc(CC(N)C)cc1C
InChI InChI=1S/C11H15NO2/c1-7-3-9(4-8(2)12)5-10-11(7)14-6-13-10/h3,5,8H,4,6,12H2,1-2H3 Key:OLENSVFSNAULML-UHFFFAOYSA-N
(what is this?)  (verify)

5-Methyl-3,4-methylenedioxyamphetamine (5-Methyl-MDA) is an entactogen and psychedelic designer drug of the amphetamine class. It is a ring-methylated homologue of MDA and a structural isomer of MDMA.

Effects and research

This section appears to contradict itself. Please see the talk page for more information. (June 2016)

This section relies excessively on references to primary sources. Please improve this section by adding secondary or tertiary sources. Find sources: "5-Methyl-MDA" – news · newspapers · books · scholar · JSTOR (June 2016) (Learn how and when to remove this message)

Drug discrimination studies showed that 5-methyl-MDA substitutes for MDA, MMAI, and LSD, but not amphetamine, suggesting that it produces a mix of entactogen and hallucinogenic effects without any stimulant effects.

5-Methyl-MDA acts as a selective serotonin releasing agent (SSRA) with IC₅₀ values of 107nM, 11,600nM, and 1,494nM for serotonin, dopamine, and norepinephrine efflux. It is over 5 times more potent than MDA in vitro assays, with a suitable active dose possibly in vivo being around 15–25 mg. Subsequent testing in vivo, however, has found that it is not as potent as once thought and is active at at least 100 mg. 2-Methyl-MDA is also much more potent than MDA, but is not quite as potent as 5-methyl-MDA. 6-methyl-MDMA (also known as Madam-6) is mostly inactive, likely due to steric hindrance.

Recent research has used data on 2-methyl-MDA and 5-methyl-MDA to help guide computer modeling of the serotonin transporter complex.

Legal status

5-Methyl-MDA is not scheduled by the United Nations' Convention on Psychotropic Substances.

United States

5-Methyl-MDA is not scheduled at the federal level in the United States, but it is possible that 5-Methyl-MDA could legally be considered an analog of MDA, in which case, sales or possession could potentially be prosecuted under the Federal Analogue Act.

References

1. ^ Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 41 (6): 1001–5. doi:10.1021/jm9705925. PMID 9526575.
2. PIHKAL #98
3. Walline CC, Nichols DE, Carroll FI, Barker EL (June 2008). "Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 791–800. doi:10.1124/jpet.108.136200. PMC 2637348. PMID 18354055.
4. "Convention on Psychotropic Substances, 1971". Archived from the original on 2022-01-19. Retrieved 2016-06-09.
5. "§1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2016-06-09.
6. Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary

• Drugs not assigned an ATC code
• Entactogens and empathogens
• Substituted amphetamines
• Benzodioxoles
• Designer drugs
• Serotonin releasing agents